SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported an open-market sale of 17,685 Ordinary Shares at an average price of $5.2772 per share. According to the filing, the shares were sold to satisfy tax withholding obligations tied to restricted stock units that vested on July 3, 2026, under a pre-established Rule 10b5-1(c) trading plan. After this transaction, Camblong directly holds 3,541,122 Ordinary Shares, indicating the sale is small relative to his remaining stake and was executed on a non-discretionary basis.
SOPH reported Rule 144/Form 144 sale activity by a holder under a pre-arranged 10b5-1 plan, reporting multiple open-market dispositions of Common shares. The filings list individual 10b5-1 sales across multiple dates in 2026, including trades of 65,269 shares on 06/30/2026 and 50,069 shares on 06/26/2026. The record also shows holdings from Restricted Stock Units and Founders Shares with grant dates of 07/02/2026 and 03/18/2021, respectively.
SOPHiA GENETICS SA Chief Financial Officer George Cardoza sold 1,592 Ordinary Shares in an open‑market transaction. The weighted average sale price was $5.2886 per share. According to the disclosure, the sale was made to cover tax withholding obligations from restricted stock units that vested on July 2, 2026 and was executed under a pre‑established Rule 10b5‑1(c) trading plan. After this tax‑related sale, Cardoza directly holds 309,092 Ordinary Shares.
SOPHiA GENETICS SA Chief People Officer Manuela Valente sold 4,241 Ordinary Shares in an open-market transaction. The shares were sold at a weighted average price of $5.053 per share to cover tax withholding obligations tied to restricted stock units vesting on July 2 and July 3, 2026, under a pre-established Rule 10b5-1(c) trading plan. After this sale, she directly holds 210,450 Ordinary Shares.
SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma reported a sale of 5,285 Ordinary Shares in an open-market transaction. The weighted average sale price was about $5.10 per share, with individual trades between $4.97 and $5.41.
According to the footnotes, these shares were sold to satisfy tax withholding obligations tied to restricted stock units that vested on July 2 and July 3, 2026. The transactions were executed under a pre-established Rule 10b5-1(c) trading plan and are described as non-discretionary. After the sale, Verma directly holds 192,171 Ordinary Shares.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu sold 7,393 Ordinary Shares in an open-market transaction at a weighted average price of $5.1727 per share. The sale was executed to cover tax withholding obligations from recent restricted stock unit vesting under a pre-established Rule 10b5-1(c) trading plan and does not represent a discretionary trade. Following this transaction, Xu directly holds 614,887 Ordinary Shares, indicating he retains a large continuing stake in the company.
SOPHiA GENETICS SA Chief Executive Officer Ross Muken reported an open-market sale of 9,838 Ordinary Shares at a weighted average price of $5.22 per share. According to the footnotes, the sale was made solely to satisfy tax withholding obligations tied to restricted stock units that vested on July 2 and July 3, 2026, under a pre-established Rule 10b5-1(c) trading plan and was not a discretionary trade. Following these transactions, he directly holds 670,651 Ordinary Shares. The shares were sold in multiple trades at prices between $4.97 and $5.43.
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported small insider sales tied to tax obligations. On July 6, 2026, he sold a total of 216 Ordinary Shares in open-market transactions at prices between $5.0251 and $5.0862 per share.
According to the footnotes, these were non-discretionary “sell to cover” trades executed to satisfy taxes from restricted stock units that vested on July 2 and July 3, 2026. After these transactions, he continues to hold 147,948 Ordinary Shares directly.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu sold 7,393 ordinary shares of the company on July 6, 2026 at a weighted average price of $5.1611 per share. According to the disclosure, these open-market sales were made to satisfy tax withholding obligations from restricted stock units that vested on July 2 and July 3, 2026, and were executed under a pre-established Rule 10b5-1(c) trading plan, meaning they were not discretionary trades. After the sale, Menu directly holds 233,387 ordinary shares, indicating he maintains a substantial ongoing equity position in the company.
SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported an open-market sale of 22,486 Ordinary Shares at a weighted average price of $5.255 per share. According to the filing, the sale was made to satisfy tax withholding obligations from restricted stock unit vesting and was executed under a pre-established Rule 10b5-1(c) trading plan, described as non-discretionary. After this transaction, he directly holds 3,558,807 Ordinary Shares.